Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA) Valuation According to the Numbers

In order to determine if a company is fairly valued, we can look at a number of different ratios and metrics.  First off we’ll take a look at the Price to Cash Flow ratio of Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA).  The firm currently has a P/CF ratio of -12.924728.

This is the current Price divided by Cash Flow Per Share for the trailing twelve months. Cash Flow is defined as Income After Taxes minus Preferred Dividends and General Partner Distributions plus Depreciation, Depletion and Amortization.

Investors might be searching high and low for the next great stock to trade. Professional investors may have their game plans honed and ready to roll, but amateurs may be fighting to stay above water in the markets. Leaping into the equity markets without any preparation may lead to quick losses. Keeping track of all the ins and outs of daily market activity can be exhausting, and investors may be best served if they are able to focus on the essentials and rise above the noise. Although successful trading might be measured differently from one person to another, the general principles of winners are generally the same. Snatching profits from the market may seem like an easy task when stocks are soaring, but things can always snap back in the blink of an eye. Investors who are able to prepare for any situation may find themselves ahead of the game when the inevitable bear market scenario rears its head.

Profitability

The Return on Invested Capital (aka ROIC) for Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA) is -5.569549.  The Return on Invested Capital is a ratio that determines whether a company is profitable or not.  It tells investors how well a company is turning their capital into profits.  The ROIC is calculated by dividing the net operating profit (or EBIT) by the employed capital.  The employed capital is calculated by subrating current liabilities from total assets.  Similarly, the Return on Invested Capital Quality ratio is a tool in evaluating the quality of a company’s ROIC over the course of five years.  The ROIC Quality of Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA) is -2.041985.  This is calculated by dividing the five year average ROIC by the Standard Deviation of the 5 year ROIC.  The ROIC 5 year average is calculated using the five year average EBIT, five year average (net working capital and net fixed assets).  The ROIC 5 year average of Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA) is -5.695220.

Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA) has a Price to Book ratio of 4.021353. This ratio is calculated by dividing the current share price by the book value per share. Investors may use Price to Book to display how the market portrays the value of a stock. Checking in on some other ratios, the company has a Price to Cash Flow ratio of -12.924728, and a current Price to Earnings ratio of -10.344649. The P/E ratio is one of the most common ratios used for figuring out whether a company is overvalued or undervalued.

After a recent scan, we can see that Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA) has a Shareholder Yield of -0.437716 and a Shareholder Yield (Mebane Faber) of -0.69017. The first value is calculated by adding the dividend yield to the percentage of repurchased shares. The second value adds in the net debt repaid yield to the calculation. Shareholder yield has the ability to show how much money the firm is giving back to shareholders via a few different avenues. Companies may issue new shares and buy back their own shares. This may occur at the same time. Investors may also use shareholder yield to gauge a baseline rate of return.

The EBITDA Yield is a great way to determine a company’s profitability.  This number is calculated by dividing a company’s earnings before interest, taxes, depreciation and amortization by the company’s enterprise value.  Enterprise Value is calculated by taking the market capitalization plus debt, minority interest and preferred shares, minus total cash and cash equivalents.  The EBITDA Yield for Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA) is -0.126374. 

There are many different tools to determine whether a company is profitable or not.  One of the most popular ratios is the “Return on Assets” (aka ROA).  This score indicates how profitable a company is relative to its total assets.  The Return on Assets for Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA) is -0.762093.  This number is calculated by dividing net income after tax by the company’s total assets.  A company that manages their assets well will have a higher return, while a company that manages their assets poorly will have a lower return.

Quant Scores

The Gross Margin Score is calculated by looking at the Gross Margin and the overall stability of the company over the course of 8 years.  The score is a number between one and one hundred (1 being best and 100 being the worst).  The Gross Margin Score of Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA) is 50.00000.  The more stable the company, the lower the score.  If a company is less stable over the course of time, they will have a higher score.

The C-Score is a system developed by James Montier that helps determine whether a company is involved in falsifying their financial statements.  The C-Score is calculated by a variety of items, including a growing difference in net income verse cash flow, increasing days outstanding, growing days sales of inventory, increasing assets to sales, declines in depreciation, and high total asset growth.  The C-Score of Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA) is -1.00000.  The score ranges on a scale of -1 to 6.  If the score is -1, then there is not enough information to determine the C-Score.  If the number is at zero (0) then there is no evidence of fraudulent book cooking, whereas a number of 6 indicates a high likelihood of fraudulent activity. The C-Score assists investors in assessing the likelihood of a company cheating in the books.

The ERP5 Rank is an investment tool that analysts use to discover undervalued companies.  The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC.  The ERP5 of Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA) is 17555.  The lower the ERP5 rank, the more undervalued a company is thought to be.

At the time of writing, Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA) has a Piotroski F-Score of 2. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.

Checking in on some valuation rankings, Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA) has a Value Composite score of 80. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 86.

Some traders may be using technical analysis to try and beat the stock market. There are many different indicators that traders have at their disposal. The sheer amount of indicators may leave the trader wondering which ones to use. Studying different technical indicators and signals may be worthwhile and educational, but the average investor may only end up focusing on a couple different indicators that actually work. Finding which indicators to follow and trade on may take some time and effort. Scoping out the proper signals and figuring out which ones tend to work the best may be on the minds of many traders. Trying to follow too many technical indicators might not be the best idea, and it may even cause more confusion. Once the signals have been chosen, traders may spend a lot of time back testing strategies before diving into the market.